Thought people might be interested in this.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 19, 2006--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase III AIR-CF2 (CP-AI-005) study of aztreonam lysine for inhalation for the treatment of people with cystic fibrosis (CF) who have...